HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
PDF Library
RSS Feeds
Subscribe
Advertising
Partnered Content
Report Store
UsernamePublicRestriction
Tags:

RegeneRx Seeks Cosmeceutical Partners While Developing Drugs

This article was originally published in The Rose Sheet

  • News

Executive Summary

Cash-strapped Maryland biotech firm RegeneRx is in talks with global cosmetics firms to develop products from its drug candidate molecule T?4 and hopes to see revenue from cosmeceuticals by 2010

You may also be interested in...



Lauder/Allergan Marriage Delivers Clinique Medical For Cosmetic Procedures

The Estee Lauder Companies has joined with pharmaceutical firm Allergan to launch Clinique Medical, a line of skin-care products designed to prepare skin for non-surgical cosmetic procedures and assist in the healing process, the firm says Oct. 15

Elizabeth Arden To Co-Market Prevage Cream Under Allergan Deal

Elizabeth Arden is making its foray into the cosmeceutical skin care market through an exclusive co-marketing agreement with Prevage manufacturer Allergan

Rare Disease Roundtable: Dealing With Pricing Pressure

Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.

Table

View full table

Tags:
UsernamePublicRestriction

Register

RS016103

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By